

EGM Presentation

May 26th 2015

ASX: PAA
ACN 094 006 023



DISCLAIMER

- This presentation does not constitute investment advice. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sale of shares.
- Shareholders should not rely on this presentation. This presentation does not take into account any persons particular investment objectives, financial resources or other relevant circumstances and the opinions and recommendations in this presentation are not intended to represent recommendations of particular investments to particular persons.
- The information set out in this presentation does not purport to be all inclusive or to contain all the information which its recipients may require to make an informed assessment of the proposed transaction. You should conduct your own investigations and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation.

PHARMAUST LIMITED

...Fast tracking leading
edge technology in cancer
therapy....



CANCER 1

Market

- Global cancer drug spending hits \$100 billion in 2014- REF: IMS Health (includes supportive care drugs e.g. anti-emetics and treatments for anaemia)
- Cancer market is seen rising to \$117 billion to \$147 billion in 2018, IMS forecast, a compound annual growth rate of 6-8 percent

CANCER 2

Targets

Medicines that target a specific protein or genetic mutation, as opposed to chemotherapies, now account for almost half of total U.S. cancer drug spending

PPL-1 Targets mTOR, one of the most exciting recent cancer targets

CANCER 3

Partnering

Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of the high unmet need for improved treatments for multiple types of cancer

PharmAust has a Research Option Agreement with a top 5 big Pharma for Veterinary Applications of PPL-1

During 2015 we will seek a partner for the human applications of PPL-1

CANCER 4

Market Leaders

- Roche led the global cancer market with 2010 sales of \$20.6bn, which was mainly based on sales from Avastin, Herceptin, MabThera, and Xeloda.
- Novartis reported 2010 sales of \$6bn, representing an increase of 14.4% over the previous year, which positions it as the second largest pharmaceutical company in the global cancer market.

CANCER 5

The Drug Cocktail



Most of the cancer drugs in development are likely to be used in combination with other marketed options, as scientists realize the importance of a multi-targeted approach in treating the disease. New cancer drugs, therefore, have to be judged not only on the initial indication for which they were approved but also on their potential in other areas

PPL-1 Is being evaluated in multiple cancers in patients who have failed multiple therapies – The next stage is likely to examine PPL-1 in patients on chemotherapy

PPL-1 IN ADVANCED CANCER

- Advanced Cancer is a term used to describe cancer that has spread and is unlikely to be cured.
- Patients with advanced cancer have often failed “Standard of Care” and have become multidrug resistant.
- PharmAust is currently investigating PPL-1 in patients with advanced cancers

AIM OF CURRENT TRIAL WITH PPL-1

- To examine safety of PPL-1 and demonstrate the absence of adverse events
- To identify a dose of PPL-1 that shows activity on the cancer
- To demonstrate changes in tumour markers

WHERE ARE WE?

- So far no material adverse events (7 patients treated with 3 completing 28-day course)
- Completion of lowest dose cohort (dose 5mg/kg) – all patients responded to PPL-1 as measured by suppression of key cancer marker p70s6k.
- Currently recruiting for next cohort (25mg/kg)

WHAT IS THE p70s6k TUMOUR MARKER

1. Overexpression of p70S6K in cancer patients is associated with aggressive disease and poor prognosis.
2. Recent studies showed that cancer patients with increased p70S6K phosphorylation had poor survival and increased metastasis
3. Reducing the levels of p70S6K inhibits cell growth, invasion, and metastasis in cancer.
4. Inhibition of p70S6K has been shown to reduce cell growth, migration, and invasion *in vitro*.
5. Metastasis is not observed in studies where the p70S6K is down regulated in animals

CONCLUSIONS

- PPL-1 APPEARS TO HAVE BROAD ANTICANCER ACTIVITY
- PPL-1 SYNERGISES WITH CURRENT CANCER TREATMENTS
- TUMOUR MARKER P70S6K SUPPRESSED IN ALL PATIENTS TESTED AT LOWEST DOSE OF PPL-1 TESTED



THANK YOU

QUESTIONS